ROCHESTER, N.Y. (May 14, 2025)—Neuroscience technology innovator Cognivue^®, today announced a scientific breakthrough with the launch of the Cognivue Amyloid Risk Measure (CARM)*, a novel metric that predicts the likelihood of the presence of amyloid—a key biomarker of Alzheimer’s disease (AD).¹ Now available as an optional feature on the Cognivue Clarity^® device (based on FDA-cleared technology), CARM represents a significant advancement in the early detection of Alzheimer’s by helping healthcare providers identify those at risk of cognitive impairment, even before symptoms emerge.

Over time, stress and anxiety can build to a point where life’s challenges become overwhelming and cause physical effects. Now, in ACS Applied Materials & Interfaces, researchers report a dental floss pick with a built-in sensor that could monitor stress as part of a daily routine. The device, which accurately senses levels of the stress hormone cortisol in minutes, could help users recognize when it’s time to get help.

In many neurodegenerative diseases, proteins misfold and clump together in brain tissue. Scientists developed a new therapy made of peptides and a sugar that naturally occurs in plants. The therapeutic molecules self-assemble into nanofibers, which bond to the neuron-killing proteins. Now trapped, the toxic proteins can no longer enter neurons and instead harmlessly degrade.

After its new extension, which increased its computing power fourfold, the Jean Zay supercomputer is now capable of 125.9 million billion operations per second. Hosted and operated by the CNRS’s Institute for Development and Resources in Intensive Scientific Computing (IDRIS), Jean Zay, which was acquired by the French Grand Équipement National de Calcul Intensif (GENCI), has become one of France’s most powerful supercomputers. The official inauguration of this extension, which was announced by the French President, was held on Tuesday, 13 May 2025.